Huyabio International and Bristol-Myers Squibb Co. are planning to evaluate the combination of Huyabio’s HBI-8000, an epigenetic immunomodifier, and Opdivo (nivolumab), a PD-1 blocking antibody.
The European Commission has approved Cabometyx (cabozantinib) in combination Opdivo (nivolumab) for the first-line treatment of advanced renal cell carcinoma.
The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the approval of Copiktra as monotherapy for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia after at least two prior therapies and follicular lymphoma that is refractory to at least two prior systemic therapies.
FDA has approved pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal (tumors with epicenter 1 to 5 centimeters above the gastroesophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation.
Evotec SE and Takeda Pharmaceutical Company Ltd. have entered into a multi-RNA target alliance to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.
McKesson has received approval from The Centers for Medicare & Medicaid Services to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.
Mayo Clinic and Thermo Fisher Scientific are working together to evaluate next-generation sequencing, mass spectrometry and immunology diagnostic tools for multiple applications, including myeloid leukemia and therapeutic drug monitoring panels to deliver access to more precise and personalized insights for patient care.
CYNK-001, a natural killer cell therapy, has received Fast Track designation from FDA for the treatment of adults with recurrent glioblastoma multiforme.
Geneseeq Technology Inc. and Illumina Inc. are working together to develop comprehensive in-vitro diagnostic NGS testing kits (IVD kits) for cancer, using Illumina’s NextSeq 550 Dx sequencing platform.
M2Gen and Merck have entered a new five-year agreement to advance cancer research.
